e-journal
Development and validation of an in vitroein vivo correlation (IVIVC) model for propranolol hydrochloride extended-release matrix formulations
The objective of this study was to develop an in vitroein vivo correlation (IVIVC) model for
hydrophilic matrix extended-release (ER) propranolol dosage formulations. The in vitro
release characteristics of the drug were determined using USP apparatus I at 100 rpm, in a
medium of varying pH (from pH 1.2 to pH 6.8). In vivo plasma concentrations and pharmacokinetic
parameters in male beagle dogs were obtained after administering oral, ER
formulations and immediate-release (IR) commercial products. The similarity factor f2 was
used to compare the dissolution data. The IVIVC model was developed using pooled
fraction dissolved and fraction absorbed of propranolol ER formulations, ER-F and ER-S,
with different release rates. An additional formulation ER-V, with a different release rate
of propranolol, was prepared for evaluating the external predictability. The results showed
that the percentage prediction error (%PE) values of Cmax and AUC0-oo were 0.86% and
5.95%, respectively, for the external validation study. The observed low prediction errors
for Cmax and AUC0-oo demonstrated that the propranolol IVIVC model was valid.
Keywords:
IVIVC
Extended-release dosage
Propranolol
Tidak ada salinan data
Tidak tersedia versi lain